CURRENT STANDARD APPROACH TO SECONDARY PREVENTION OF ISCHEMIC, NON-CARDIOEMBOLIC STROKE OR HIGH-RISK TIA

Jun 9, 2025 | Antithrombotics

2) Our returning expert faculty is Ashkan Shoamanesh MD @Ash_Shoamanesh, #Stroke #Neurologist @HamHealthSci & Associate Professor @McMasterU. He is also Director of Hemorrhagic Stroke Research Program & Senior Scientist @PHRIresearch 🇨🇦— cardio-met...

ATTR-CM: Genetics, Pathophysiology, Early Accurate Diagnosis, and Expanding Treatment Options

May 30, 2025 | ATTR

2) #Transthyretin #Amyloid (#ATTR) #Cardiomyopathy (#ATTR_CM) is now known to be underdiagnosed & much more common than we once thought. With now 3 @US_FDA approved treatments for ATTR-CM, let's go back to the basics & re-educate ourselves on this...

The Importance to Cardiorenal Outcomes of Effective Blood Pressure Control and the Pathophysiologic Role of Aldosterone Dysregulation

May 28, 2025 | Hypertension

2) This program is intended for #HCPs & is supported by an unrestricted educational grant from AstraZeneca. Statement of accreditation & faculty disclosures at https://t.co/gvXca4G9Xm. Follow this 🧵for 0.75 hr 🆓CE/#CME credit–all delivered right here on...

UPDATE ON MANAGING THE INTERSECTION OF oHCM & HEART FAILURE: Summary of a Discussion at ESC-HF 2025

May 19, 2025 | HCM

2) We report from a symposium led by Iacopo Olivotto @IacopoOlivotto from #Firenze 🇮🇹 along w/Christoph Maack @ChristophMaack from Comprehensive 🫀Failure Ctr Würzburg 🇩🇪, Gianluigi Savarese @GianluSava HF doc from @karolinskainst 🇸🇪, & Michelle Michels from...

ACC25: New Data on ATTR-CM

Apr 28, 2025 | ATTR

2) This was a busy #ACC25 with numerous updated datasets and analyses focusing on #ATTR #CM targeted therapies. @MasriAhmadMD will cover certain selected presentations.BTW for foundational education on #ATTR_CM & #ATTR_PN see https://t.co/41keu1Y9kb...